Features:
-Nonpathogenicwithleastimmuneresponse.
-Excellentgenedeliveryefficiencyinmostcelltypesincludingdividingandnon-dividingorprimarycells.
-Persistenttransgeneexpression.
-MultipleSEROtypes(AAV-1,AAV-2,AAV-3,AAV-4,AAV-5,AAV-6,AAV-8,AAV-9,AAV-DJ/8andAAV-DJ).
Large AAVcisvectorinventory forconstructingAAVcisplasmidwith aspecificpromoterandreporter:
SinglepromoterrAAVcisvector | DualpromoterrAAVcisvector | |||
Promoterless |
| Promoterless | CMV | eGFP |
ServiceDescription:
-Cloningyourgeneofinterest(GOI)intoAAVcisvector.
-rAAVcisplasmidlargeprep.
-rAAVpackagingin1xcellstack.
-rAAVpurificationviaadvanced2xCsClultra-centrifugation.
-Desalting,filtersterilizationandAAVtitrationviaqPCR.
rAAVSerotypesWeOffer:
AAV-1,AAV-2,AAV-3,AAV-4,AAV-5,AAV-6,AAV-7,AAV-8,AAV-9,AAV-PHP.B,AAV-DJ/8andAAV-DJ.
RequiredMaterials:ANCBIaccession#orgenesymbolorplasmidDNAcarryingyourgeneofinterest(GOI).
TurnaroundTime:2~3weeks.
Deliverables:>0.2mL(4x50µL)ofsuperpurifiedinvivograderAAVvectorat>1E+13VG/mL*.
Weofferdiscountfornewcustomer,pleaserequestaquotewithustoday.
SuperHighYield:
WithourproprietarygeneticallyengineeredAAV·HT™packagingcellandaadvancedpurificationapproach,therAAVyieldiseasytoreachsuperhighlevel--------total1E+15VG.ForsuperhighlevelrAAVproductionupto1E+15VGtotal,pleasecontactustorequestaquote.
Figure1.AcomparisonofpurityandinfectivityofrAAVvectorsfromdifferentsourcesshowingsuperpurifiedandsuperinfectious(closetoclinicaltrialgrade)rAAVvectorpreparedviaouradvanceddoubleCsClultra-centrifugationapproach.
A.rAAVvectors(total1E+9VGperlane) fromdifferentsourceswereresolvedonSDS-PAGEfollowedbysilverstaining. Lane1:GMPmanufacturedrAAVvectorfromCHOP;Lane2:rAAVpreparedviaouradvanced2xCsClultra-centrifugationapproach;Lane3:rAAVfromVectorCoreofBCM;Lane4:rAAVfromourcompetitor"V";Lane5:rAAVfromourcompetitor"C";Lane6:ProteinMarker.
B.SuperinfectiousrAAVvectorpreparedviaadvanceddoubleCsClultra-centrifugation. Leftpanel:rAAV9-GFP(total5E+9VG)fromourcompetitor"V"injectedtomouseeye;Rightpanel:rAAV-9-GFP(total5E+9VG)purifiedviaadvanced2xCsClultra-centrifugationinjectedtomouseeye.
Figure2.AcomparisonofinfectivityofrAAVvectorsfromdifferentsourcesshowingsuperpurifiedrAAVpreparedviaadvanceddoubleCsClultra-centrifugationapproachissuperinfectious.
rAAV1-GFP(total2E+9VG)fromdifferentsourceswereinjectedtomousemuscletissue. TheGFPfluorescencewasvisualized3weekspostinjection. A.rAAV1-GFPfromourcompetitor"V";B.rAAV1-GFPfromourpre-maderAAVsstockpurifiedviaadvanceddoubleCsClultra-centrifugation. C.QuantificationdatashowedthatoursuperpurifiedrAAV(bar2)is~9timesmoreinfectiousthanthat(bar1)preparedviaconventionalCsClultra-centrifugation.
*Finalviralyieldmaydependonthenatureoftransgene.
SignaGen公司是一家专注于开发和生产基因转导工具的企业,服务于生物医学研究领域。借助我们独有的技术平台(美国专利商标局号码为 072308和61135606),SignaGen已经成功开发出三大类 DNA/siRNA转染试剂,经验证我们的产品比市场上主导产品效率更高,细胞毒性更低。更重要的是我们提供一个合理的价位。